Replies to post #18487 on GTC Biotherapeutics (fka GTCB)

[read_this_n0w]

What is it with the 'partner will fix everything' mantra ?

late 2008 loan by LEO to gtcb will dilute shareholder value at 0,31 if not redeemed before te summer.... and on top of that the remainder of 2009 has to be financed as well.
Why does no long ever project cash use needed to redeem the loan and finance further 9-12 months of operations?

That is no small sum of money for company with gtcb's market cap.

Also, both the old LFB Deal and as recently as the ovation deal: gtcb has been keen on decent longterm arrangements with paltry upfront payments so far, its why the company goes back to shareholder dilution time and again to finance themselves. in the past gtcb has allways choosen to be development partner, increasing cost and risk , instead of focussing on short and midterm cash flow as well.

As for the 'partner will fix everything' mantra : Recent deal with new zealand's Ag was not the big pharma people had in their mantra as recently as two weeks ago....

but now more partners will come, not only that but they will finance a bucket of cash upfront?

Odds are much higher that even if another partner comes soon, cash will be low and shareholders will see more dilution.